In my view the Achillies heel for Mylan in this arbitration matter has always been the original filing of a an improved daptomycin patent by Agila 3 or4 years ago.It also worth also worth noting that this patent represents another validation of TPM technology.That gives 3 independent technology validations from the likes of Novartis,Agila /Strides and Terumo.
Kens
Mylan Or Bust?, page-22
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $408 | 154.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 90794613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 54998583 | 13 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |